



Frequent anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without 
CN54rgp140/GLA-AF in Healthy Tanzanian and Mozambican Volunteers 
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CONCLUSION 
Anti-V1V2 responses were frequently detected after HIV-DNA 
prime followed by HIV-MVA boosting. Co-administration of 
CN54rgp140/GLA-AF with HIV-MVA did not increase the 




We evaluated the impact of co-administration of CN54rgp140/GLA-AF with HIV-MVA after 
HIV-DNA priming on anti-V1V2 responses and antibody-dependent cellular cytotoxicity 
(ADCC)-mediating antibodies, shown to be associated with reduced risk of HIV 
acquisition in the RV144 trial (1). 
METHODS 
High anti-V1V2 total IgG response rates to A244 and CN54 were 
detected in both groups of vaccinees; HIV-MVA alone and HIV-MVA
+rgp140. Anti-V1V2 A244 responses were predominantly IgG1. Anti-
V1V2 IgG3 responses to A244  were more frequent in HIV-MVA than 
in HIV-MVA+rgp140 recipients. Anti-V1V2 IgG1 and anti-V1V2 IgG3 
responses to CN54 were rare. Placebos were negative. 
  
The frequency and magnitude of ADCC mediating antibodies to 
CM235 CRF01_AE infected cells were not significantly different 
between the two boost groups. 
The magnitude of anti-V1V2 total IgG and IgG1 responses to 
A244 and CN54 was not significantly different between the two 
boost groups.  
For graphing, plasma samples with no V1V2 IgG1 and V1V2 
IgG3 antibody responses at 1:100 dilutions were arbitrarily 
assigned a value of 20. The dotted line indicates the cut off for 
positive values. 
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Healthy HIV-uninfected adults (N=191) in the TaMoVaC II phase IIa trial were randomized 
twice; first to one of three HIV-DNA intradermal priming regimens by needle-free 
ZetaJetTM device at weeks 0, 4 and 12 (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL 
[3mg/mL] plus electroporation (EP), Group III: 1x0.1mL [6mg/mL] plus EP). Second the 
same volunteers received 108 pfu HIV-MVA twice, alone or combined with CN54rgp140/
GLA-AF, intramuscularly by syringe, 16 weeks apart. Additionally, 20 volunteers received 
saline placebo (2). Plasma was collected four weeks after the final vaccination (n=145), 
and a subset (57 vaccinees and 9 placebos) was tested for binding antibodies to 
gp70V1V2 proteins of CRF01_AE (A244) and subtype C (CN54) using ELISA. ADCC 
activity was measured in 145 samples using a luciferase assay employing CRF01_AE  





Frequency of responses  
(Four weeks after the final immunization) 
   HIV-MVA HIV-MVA+rgp140 P value 
IgG A244 CRF01_AE 25/31 (81%) 18/25 (72%) 0.532 
IgG CN54 C 20/31 (65%) 15/25 (60%) 0.786 
IgG1 A244 CRF01_AE 25/32 (78%) 19/25 (76%) 1 
IgG1 CN54 C 0/32   (0%) 2/25   (8%) 0.188 
IgG3 A244 CRF01_AE 12/32 (38%) 2/25   (8%) 0.013 
IgG3 CN54 C 0/32   (0%) 1/25   (4%) 0.448 	
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HIV-MVA: Gag A, Pol A, Env E 
± CN54rgp140: Clade C/GLA-AF 
HIV-DNA: Gag A,B, RTmutB 
                 Env A,B,C, RevB 

















IMC CM235 Infected target cells
Vaccination 
group 
Frequency of ADCC 
mediating antibodies 
P value 
HIV-MVA  16/76 (21%) 
0.393 HIV-MVA + 
rgp140 
10/66 (15%) 
	
